Mammoscintigraphie 99mTc MIBI données de la littérature et résultats de l'étude multicentrique française

Medecine Nucleaire

Volumn 22, Issue 9, 1998, Pages 498-507

  Corone, C ^a   Stevens, D ^a   Muratet, J P ^b   Switsers, O ^b   Boneu, A ^b   Carpentier, P ^b   Liehn, J C ^b   Mestas, D ^b   Bonichon, F ^b   Edeline, V ^b   Fonroget, J ^b   Cherel, P ^a   Hagay, C ^a   Nogues, C ^a   Becette, V ^a   Pecking, A ^a   Petras, S ^b   Hermans, J ^b   Maublant, J ^b  

^a CENTRE RENÉ HUGUENIN   (France)

^b Service de Médecine Nucléaire ^*

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0004478054     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Muller S., Guth-Tougelides B. and Creutzig H. Imaging of malignant tumours with Tc 99m MIBI SPECT. J Nucl Med 1987; 28: 562 (résumé).
2. Yen T.C., Lin H.D., Lee C.H., Chang S.L. and Yeh S.H. The role of Technetium 99m sestamibi whole body scans in diagnosing metastatic Hurtle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine 131 and thallium 201 whole body scans. Eur J Nucl Med 1994; 21: 980-983.
3. Maffioli L., Steens J., Pauwels E., Bombardieri E. Applications of 99mTc-sestamibi in oncology. Tumori 1996; 82: 12-21.
4. Look R.M., Lim S.W., Waxman A.D., Gupta P.K., Fuerst M.M., Kusuanco D.A., Lawrence G.N., Giles F.J. Technetium-99m sestamibi scanning in multiple myeloma stem cell transplantation. Leuk Lymphoma 1996; 20: 453-456
5. Piwnica-Worms D., Kronauge J.F. and Chiu M.L. Enhancement by tetraphenylborate of technetium - 99m - MIBI uptake kinetics and accumulation in cultured chick myocardial cells. J Nucl Med 1991; 32: 1992-1999.
6. Carvalho P.A., Chiu M.L., Kronauge J.F., Kawamura M., Jones A.G., Holman B.L. and Piwnica-Worms D. Subcellular distribution and analysis of technetium - 99m - MIBI in isolated perfused rat hearts. J Nucl Med 1992; 33: 1516-1521.
7. Delmon-Moingeon L.I., Piwnica-Worms D., Van Den Abeele A.D., Holman B.L., Davidson A. and Jones A.G. Uptake of the cation hexakis (2 methoxyisobutylisonitrile) - technetium 99m by human carcinoma cell lines in vitro. Canc Res 1990; 50: 2198-2202.
8. Maublant J.C., Zhang Z., Rapp M., Ollier M., Michelot J. and Veyre A. In vitro uptake of technetium 99m teboroxime in carcinoma cell lines and normal cells: comparison with Technetium 99m-SestaMIBI and Thallium- 201. J Nucl Med 1993; 34: 1949-1952.
9. Piwnica-Worms D., Chin M.L., Budding M., Kronauge J.F., Kramer R.A., Croop J.M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993; 53: 977-984.
10. Aktolun C., Bayhan H. and Kir M. Clinical experience with 99 m Tc MIBI imaging in patients with malignant tumors. Preliminary results and comparison with Tl-201. Clin Nucl Med 1992; 17: 171-176.
11. Khalkhali I., Mena I., Jouanne E., Diggles L., Venegas R., Block J., Alle K. and Klein S. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg 1994; 178: 491-497.
12. Diggles L., Mena I. and Khalkhali I. Technical aspects of prone dependant breast scintimammography. J Nucl Med Tech 1994; 22: 165-170.
13. Khalkhali I., Cutrone J., Mena I., Diggles L., Venegas R., Vargas H., Jackson B., Klein S. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med 1995; 36: 1784-1789.
14. Khalkhali I., Iraniha S., Diggles L.E., Cutrone J.A., Mishkin F.S. Scintimammography: the new role of technetium-99m Sestamibi imaging for the diagnosis of breast carcinoma. Q J Nucl Med 1997; 41: 231-238.
15. Palmedo H., Biersack H.J., Lastoria S., Maublant J., Prats E., Stegner H.E., Bourgeois P., Hustinx R., Hilson A.J.W., Bischof-Delaloye A. Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective european multicenter trial. Eur J Nucl Med 1998; 25: 375-385.
16. Waxman A., Nagaraj N., Kovalesky M., Phillips E., Yadegar J., Silberman A and Memsic L. Detection of primary breast malignancy with 99m Tc MIBI in patients with non palpable primary malignancies: the importance of lesion size. J Nucl Med 1995; 36: 194P (résumé).
17. Buvat I., De Sousa M.C., Di Paola M., Ricard M., Lumbroso J., Aubert B. Impact of scatter correction in planar scintimammography: a phantom study. J Nucl Med 1998; 39: 1590-1596.
18. Pani R., Scopinaro F., Pellegrini R., Soluri A., Pergola A., De Vincenti G., Lerardi M., Weinberg I.N. Single tube gamma camera for scintimammography. Anticancer research 1997; 17: 1651-1654.
19. Scopinaro F., Schillaci O., Scarpini M., Mingazzini P.L., Di Macio L., Banci M. and all. Technetium 99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 1994; 21: 984-987.
20. Helbich T.H., Becherer A., Trattnig S., Leitha T., Kelkar P., Seifert M., Gnant M., Staudenherz A., Rudas M., Wolf G., Mostbeck G.H. Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibi scintimammography. Radiology 1997; 20: 421-429.
21. Tiling R., Sommer H., Pechmann M., Moser R., Kress K., Pfluger T., Tatsch K., Hahn K. Comparison of technetium-99m-sestamibi scintimammography with contrast-enhanced MRI for diagnosis of breast lesions. J Nucl Med 1997; 38: 58-62.
22. Uriate I., Carril J.M., Quirce R., Gutierrez-Mendgughia C., Blanco I., Banzo I., Vega A., Hernandez A. Optimisation of X-ray mammography and technetium-99m methoxyisonitrile scintimammography in the diagnosis of non-palpable breast lesions. Eur J Nucl Med 1998; 25: 491-496.
23. Lam W.W., Yang W.T., Chan Y.L., Stewart I.E., Metreweli C., King W. Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound and conventional mammography. Eur J Nucl Med 1996; 23: 498-503.
24. Perre C.I., Rutter J.E., Vos P.A., de Hooge P. Technetium-99m-sestamibi uptake in axillary lymph node metastases in breast cancer patients. Eur J Surg Oncol 1997; 23: 142-144.
25. Taillefer R., Robidoux A., Lambert R., Turpin S., Laperriere J. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995; 36: 1758-1765.
26. Maublant J., de Latour M., Mestas D., Clemenson A., Charrier S., Feillel K, Le Bouedec G., Kaufmann P., Dauplat J., Veyre A. Technetium-99m-sestamibi uptake in breast tumor and associated lymph nodes. J Nucl Med 1996; 37: 922-925.
27. Cwikla J.B., Buscombe J.R., Kelleher S.M., Parbhoo S.P., Thakrar D.S., Hinton J., Deery A.R., Crow J., Hilson A.J. Use of 99 m Tc MIBI in the assessment of patients with suspected recurrent breast cancer. Nucl Med Comm 1998; 19: 649-655.
28. Cordobes M.D., Starzec A., Delmon-Moingeon L., Blanchot C., Kouyoumdjian J.C., Prevost G., Caglar M., Moretti J.L. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 1996; 37: 286-289.
29. Kostacoflu L., Caner B., Ugur O., Sayek I., Ruacan S., Elahi N., Aras T., Bekdik C.F. Clinical validation of the influence of MDR expression on Tc 99 m Sestamibi uptake. Eur J Nucl Med 1995; 22: 734 (résumé).
30. Vecchio S.D., Ciarmiello A., Potena M.I., Carriero M.V., Mainolfi C., Botti G., Thomas R., Cerra M., D'Aiuto G., Tsuruo T., Salvatore M. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997; 24: 150-159.
31. Luker G.D., Fracasso P.M., Dobkin J., Piwnica-Worms D. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. J Nucl Med 1997; 38: 369-372.
32. Elmore J.G., Barton M.B., Moceri V.M., Polk S., Arena P.J., Fletcher S.W. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998; 338: 1089-1096.
33. Tiling R., Khalkhali I., Sommer H., Linke R., Moser R., Willemsen F., Pfluger T., Tatsch K., Hahn K. Limited value of scintimammography and contrast-enhanced MRI in the evaluation of microcalcification detected by mammography. Nucl Med Commun 1998; 19: 55-6.